Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: A Potent, Orally Bioavailable Human CB₁/CB₂Dual Agonist with Antihyperalgesic Properties and Restricted Central Nervous System Penetration

Citations Over TimeTop 10% of 2007 papers

Abstract

Selective activation of peripheral cannabinoid CB1 receptors has the potential to become a valuable therapy for chronic pain conditions as long as central nervous system effects are attenuated. A new class of cannabinoid ligands was rationally designed from known aminoalkylindole agonists and showed good binding and functional activities at human CB1 and CB2 receptors. This has led to the discovery of a novel CB1/CB2 dual agonist, naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (13), which displays good oral bioavailability, potent antihyperalgesic activity in animal models, and limited brain penetration.

Related Papers

• → The diverse CB₁and CB₂receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin(2007)1,873 cited
• → Targeting cannabinoid agonists for inflammatory and neuropathic pain(2007)101 cited
• Pharmacology of cannabinoid receptor ligands.(1999)
• → Identification and biochemical analyses of selective CB2 agonists(2019)10 cited
• Discovery of (E)-3-(4-(Diethylamino) phenyl)-1-phenyl-2-phenylsulfonyl)prop-2-en-1-one as Novel Cannabinoid Receptor 2 Ligands(2016)